The aim of our study was to assess the prevalence of depression and anxiety in a population of patients treated for multiple sclerosis (MS) and their link with alexithymia.Method31 patients with MS according to McDonald's criteria, and followed in neurology department took part in the study. All patients were evaluated using a protocol to collect the epidemiological, clinical and evolution of the disease. We used versions of Arabized-Hospital Anxiety and Depression Scale (HADS) to assess the mood state and the Toronto Alexithymia Scale (TAS-20) for alexithymia.Results and commentsParticipants were divided on 18 women and 13 men with a mean age of 39 years. The prevalence of depression and anxiety were 42% and 52% respectively. The prevalence of alexithymia was 43%. The anxiety was correlated with the degree of disability and age of disease onset. Similarly, depression was more frequently observed in patients with higher EDSS, a long period of evolution. A positive correlation was found between alexithymia, depression and anxiety.Our study showed that half of all MS patients have mood disorders. However, depression is the most common and most disabling psychiatric disorder in MS. The place of anxiety should not be neglected because in case of comorbidity with depression, can be an aggravating factor. The frequency of alexitymia is high and appears to be positively correlated with depression and anxiety.
IntroductionThe use of conventional depots (CDs) continues to have a great importance in our psychiatric sectors due to the unavailability of atypical depot formulations.ObjectiveThe aim of this work was to assess psychiatric nurses’ perspectives of CDs.MethodsForty nurses from our psychiatric department completed a questionnaire which included both open and multiple choice questions concerning the following topics:-CDs and improvement in adherence to treatment,-efficacy and tolerance of CDs,-interest and indications of CDs.Results*Psychiatric nurses (PNs) reported that CDs allowed avoidance of oblivion (83%) and regular intake of treatment (54%). But, several PNs believed that the injections of CDs were complex (67%) and the majority considered that CDs did not have positive impact on patient adherence (85%).*PNs thought that CDs :-were more effective (fewer relapses 56%) and better tolerated than oral formulations.-did not require more precautions (80%).-provided more security to the patient (no risk of toxicity 97%).*PNs reported lots of indications: lack of family support (75%), multiple relapses (72%), poor adherence (70%) and self or hetero-aggressive behavior at relapse (52%).They supported the advantages of CDs: improving social life (85%) and patient's autonomy (68%) and permitting remission (25%).ConclusionThe findings suggest that PNs have positive attitude towards efficacy and tolerance of CDs but negative ideas about their indications, which could be the cause of patient stigmatization. That's why providing a clear piece of information seems necessary.
Distribution électronique Cairn.info pour John Libbey Eurotext. © John Libbey Eurotext. Tous droits réservés pour tous pays.La reproduction ou représentation de cet article, notamment par photocopie, n'est autorisée que dans les limites des conditions générales d'utilisation du site ou, le cas échéant, des conditions générales de la licence souscrite par votre établissement. Toute autre reproduction ou représentation, en tout ou partie, sous quelque forme et de quelque manière que ce soit, est interdite sauf accord préalable et écrit de l'éditeur, en dehors des cas prévus par la législation en vigueur en France. Il est précisé que son stockage dans une base de données est également interdit.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.